Abstract | BACKGROUND: Elevated prolactin levels are associated with increased cardiometabolic risk. No previous study has compared the effect of hypolipidemic therapy on plasma levels of lipids and other cardiometabolic risk factors in patients with and without hyperprolactinemia. METHODS: RESULTS: CONCLUSIONS: The results of our study indicate that cardiometabolic effects of fenofibrate depend on plasma prolactin levels.
|
Authors | Robert Krysiak, Witold Szkróbka, Bogusław Okopień |
Journal | Pharmacological reports : PR
(Pharmacol Rep)
Vol. 71
Issue 1
Pg. 61-66
(Feb 2019)
ISSN: 2299-5684 [Electronic] Switzerland |
PMID | 30469130
(Publication Type: Journal Article)
|
Copyright | Copyright © 2018. Published by Elsevier B.V. |
Chemical References |
- Biomarkers
- Dopamine Agonists
- Hypolipidemic Agents
- Lipids
- Bromocriptine
- Prolactin
- Fenofibrate
|
Topics |
- Adult
- Age Factors
- Biomarkers
(blood)
- Bromocriptine
(therapeutic use)
- Cardiovascular Diseases
(blood, diagnosis, drug therapy, etiology)
- Case-Control Studies
- Dopamine Agonists
(therapeutic use)
- Dyslipidemias
(blood, complications, diagnosis, drug therapy)
- Female
- Fenofibrate
(therapeutic use)
- Humans
- Hyperprolactinemia
(blood, complications, diagnosis, drug therapy)
- Hypolipidemic Agents
(therapeutic use)
- Lipids
(blood)
- Middle Aged
- Prolactin
(blood)
- Risk Factors
- Sex Factors
- Time Factors
- Treatment Outcome
- Young Adult
|